Dr. Reddy's Laboratories Limited Total Liabilities
Dr. Reddy's Laboratories Limited total liabilities. Based on the latest financial reports, Dr. Reddy's Laboratories Limited (RDDA) has total liabilities worth €187.14 Billion EUR (≈ $218.79 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Dr. Reddy's Laboratories Limited liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Dr. Reddy's Laboratories Limited (2017–2025)
Total liabilities of Dr. Reddy's Laboratories Limited from 2017 to 2025. This chart illustrates how Dr. Reddy's Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. Explore Dr. Reddy's Laboratories Limited strategic investment ratio to see how much of total assets are deployed in long-term investments.
Dr. Reddy's Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Dr. Reddy's Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DEUTSCHE WOHNEN ADRS/1/2
F:DWNP
|
Germany | €12.83 Billion |
|
Krka d. d
WAR:KRK
|
Poland | zł695.76 Million |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $380.21 Million |
|
BIM Birlesik Magazalar AS
IS:BIMAS
|
Turkey | TL225.44 Billion |
|
Autoliv Inc
ST:ALIV-SDB
|
Sweden | Skr5.86 Billion |
|
Mohawk Industries Inc
NYSE:MHK
|
USA | $5.28 Billion |
|
Keyera Corp.
TO:KEY
|
Canada | CA$10.70 Billion |
|
Avantor Inc
NYSE:AVTR
|
USA | $5.97 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Dr. Reddy's Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RDDA current and non-current assets.
Liquidity & Leverage Metrics
Dr. Reddy's Laboratories Limited Total Liabilities Ratios Explained
Dr. Reddy's Laboratories Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dr. Reddy's Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dr. Reddy's Laboratories Limited (2017–2025)
The table below shows the annual total liabilities of Dr. Reddy's Laboratories Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €155.82 Billion ≈ $182.17 Billion |
+45.67% |
| 2024-03-31 | €106.97 Billion ≈ $125.06 Billion |
+18.87% |
| 2023-03-31 | €89.99 Billion ≈ $105.21 Billion |
-15.21% |
| 2022-03-31 | €106.13 Billion ≈ $124.07 Billion |
+17.25% |
| 2021-03-31 | €90.51 Billion ≈ $105.82 Billion |
+17.16% |
| 2020-03-31 | €77.25 Billion ≈ $90.32 Billion |
-9.36% |
| 2019-03-31 | €85.23 Billion ≈ $99.64 Billion |
-14.03% |
| 2018-03-31 | €99.14 Billion ≈ $115.91 Billion |
+3.52% |
| 2017-03-31 | €95.78 Billion ≈ $111.97 Billion |
-- |
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more